Robert Pytlik

Dr. Robert Pytlik


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2009 in Cancer
Verified
Journal Article
Closed access
PDF file
MRM. A. Rodriguez
M. A. Rodriguez
RPRobert Pytlik
Robert Pytlik
TKTomas Kozak
Tomas Kozak
MCMukesh Chhanabhai
Mukesh Chhanabhai
RGRandy Gascoyne
Randy Gascoyne
JWJane N. Winter
Jane N. Winter

29 February 2016 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MKMagdalena Klanova
Magdalena Klanova
LALadislav Andera
Ladislav Andera
JBJan Brazina
Jan Brazina
JSJan Svadlenka
Jan Svadlenka
SBSimona Benesova
Simona Benesova
PKPavel Klener
Pavel Klener
Purpose: To investigate the roles of BCL2, MCL1, and BCL-XL in the survival of diffuse large B-cell lymphoma (DLBCL).

11 November 2010 in Cells Tissues Organs
Verified
Journal Article
Closed access
JKJana Karbanova
Jana Karbanova
TSTomáš Soukup
Tomáš Soukup
Jakub SuchanekJakub Suchanek
Jakub Suchanek
RPRobert Pytlik
Robert Pytlik
Denis CorbeilDenis Corbeil
Denis Corbeil
JMJaroslav Mokrý
Jaroslav Mokrý
We isolated and expanded stem cells from dental pulp from extracted third molars using an innovative culture method consisting of low serum-containing medium supplemented with epidermal growth factor and platelet-derived growth factor BB. We evaluated the differentiation potential of these cells when they were growing either adherently or as micromass/spheroid cultures in various media. Undifferentiated and differentiated cells were analyzed by flow cytometry, immunocytochemistry and immunoblotting. The flow cytometry results showed that the dental pulp stem cells (DPSCs) were positive for mesenchymal stromal cell markers, but negative for hematopoietic markers. Immunocytochemical and/or immunoblotting analyses revealed the expression of numerous stem cell markers, including nanog, Sox2, nestin, Musashi-1 and nucleostemin, whereas they were negative for markers associated with differentiated neural, vascular and hepatic cells. Surprisingly, the cells were only slightly positive for α-smooth muscle actin, and a heterogeneous expression of CD146 was observed. When cultured in osteogenic media, they expressed osteonectin, osteopontin and procollagen I, and in micromass cultures, they produced collagen I. DPSCs cultured in TGF-β1/3-supplemented media produced extracellular matrix typical of cartilaginous tissue. The addition of vascular endothelial growth factor to serum-free media resulted in the expression of endothelial markers. Interestingly, when cultured in neurogenic media, DPSCs exhibited de novo or upregulated markers of undifferentiated and differentiated neural cells. Collectively, our data show that DPSCs are self-renewing and able to express markers of bone, cartilage, vascular and neural tissues, suggesting their multipotential capacity. Their easy accessibility makes these cells a suitable source of somatic stem cells for tissue engineering.

1 December 2002 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
RPRobert Pytlik
Robert Pytlik
PBP Beneš
P Beneš
MPM Patorková
M Patorková
ECE Chocenská
E Chocenská
EGE Gregora
E Gregora
TKT Kozák
T Kozák
We conducted a controlled, double-blind study of parenteral glutamine supplementation in an unselected group of consecutive autologous transplant patients. Patients received 30 g of alanyl-glutamine dipeptide (Dipeptiven; Fresenius-Kabi, Bad Homburg, Germany) or glutamine-free amino acid solution i.v. from day +1 to day +14 or to discharge. All patients were assessed for clinical status, mucositis, blood counts, oral intake and immune reconstitution. Parenteral nutrition was administered according to predefined guidelines. Forty patients were randomized; 21 into the glutamine and 19 into the placebo arm. Glutamine patients had less days with diarrhoea (3.3 ± 4.0 vs4.3 ± 3.0, P = 0.03), but they had more severe oral mucositis (mean 4 ± 4.7 vs 1.4 ± 2.3 days of mucositis score >13, P = 0.04), spent more days on opioids (mean 3.5 ± 4.2 vs 1.2 ± 2.2 days, P = 0.03) and left hospital later than placebo patients (mean 13.5 ± 3.1 vs 11.7 ± 2.4 days after transplant, P = 0.06). There were more relapses (P = 0.02) and deaths (P = 0.05) in the glutamine group. The cost of supportive care (mean 2960 ± 1694 vs 1534 ± 513 Euro, P = 0.002) was also greater for glutamine patients, mainly due to the cost of glutamine dipeptide itself. The described mode and dosage of glutamine administration did not produce meaningful benefit in our autologous transplant patients and it was certainly not cost-effective.

1 March 2000 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
TKT Kozák
T Kozák
EHEva Kubala Havrdová
Eva Kubala Havrdová
JPJ Pit'HA
J Pit'HA
EGE Gregora
E Gregora
RPRobert Pytlik
Robert Pytlik
ŠVŠ Vodvářková
Š Vodvářková

1 June 2007 in JACC
Verified
Journal Article
Closed access
MPMartin Penicka
Martin Penicka
JHJan Horak
Jan Horak
PKPetr Kobylka
Petr Kobylka
RPRobert Pytlik
Robert Pytlik
TKTomas Kozak
Tomas Kozak
PWPetr Widimsky
Petr Widimsky